Myelin Basic Protein (MBP) (68-82), guinea pig is a fragment of myelin basic protein (MBP).
CAT No: R1522
CAS No:98474-59-0
Synonyms/Alias:98474-59-0;Myelin Basic Protein (MBP) (68-82), guinea pig;(Des-Gly77,Des-His78)-Myelin Basic Protein (68-84) (guinea pig);(Des-Lys38)-M65;MBP (68-82), guinea pig;MFCD00076872;AKOS040763894;DA-69144;FD109984;TS-10292;(Des-Gly77,Des-His78)-Myelin Basic Protein (68-84) (guinea pig) (H-Tyr-Gly-Ser-Leu-Pro-Gln-Lys-Ser-Gln-Arg-Ser-Gln-Asp-Glu-Asn-OH);L-Asparagine,l-tyrosylglycyl-L-seryl-L-Leucyl-L-prolyl-L-glutaminyl-L-Lysyl-L-seryl-L-glutaminyl-L-arginyl-L-seryl-L-glutaminyl-l-a-aspartyl-l-a-glutamyl-(9ci);
Myelin Basic Protein (MBP) (68-82), guinea pig, is a synthetic peptide fragment derived from the central nervous system myelin sheath protein of the guinea pig. As a well-characterized immunodominant epitope, MBP (68-82) plays a crucial role in neuroimmunological research, particularly in studies modeling autoimmune responses and demyelinating disorders. Its defined amino acid sequence and established immunogenicity make it a valuable tool for elucidating mechanisms underlying myelin-specific T cell activation, tolerance, and pathogenesis in experimental systems. Researchers utilize this peptide to dissect antigen-specific immune responses, investigate neuroinflammatory pathways, and develop targeted assays for myelin-associated processes.
Autoimmunity Modeling: MBP (68-82) is widely employed in the induction and study of experimental autoimmune encephalomyelitis (EAE), an established animal model for multiple sclerosis research. By introducing this peptide into susceptible rodent strains, investigators can reliably trigger T cell-mediated demyelination and central nervous system inflammation, enabling controlled analysis of autoimmune pathogenesis, immunoregulatory mechanisms, and the efficacy of immunomodulatory compounds. The reproducible immunogenic properties of the peptide facilitate comparative studies of disease progression and therapeutic intervention.
T Cell Epitope Mapping: In immunological research, MBP (68-82) serves as a prototypical antigenic peptide for mapping T cell receptor specificity and identifying key residues involved in immune recognition. By utilizing this peptide in in vitro assays such as T cell proliferation, cytokine release, and MHC binding studies, scientists can characterize the fine specificity of myelin-reactive T cell populations. These investigations are essential for understanding antigen presentation, T cell activation thresholds, and the molecular basis of self-tolerance versus autoimmunity.
Antigen-Specific Immunoassays: The defined sequence of MBP (68-82) enables its application in the development of sensitive immunoassays, including ELISA and ELISPOT formats, for the detection and quantification of MBP-specific antibodies or T cells in biological samples. These assays are instrumental in monitoring immune responses in experimental models, evaluating immunization protocols, and screening for immunogenicity in preclinical studies. The peptide's high solubility and stability further support its utility in standardized assay development.
Tolerance Induction Studies: MBP (68-82) is a preferred reagent for investigating mechanisms of antigen-specific tolerance induction in both in vivo and in vitro settings. By administering the peptide under tolerogenic conditions, researchers can assess the potential for peripheral tolerance, anergy, or regulatory T cell induction against myelin antigens. These studies provide critical insights into strategies for modulating autoimmunity and developing antigen-specific immunotherapies for demyelinating diseases.
Peptide-Protein Interaction Analysis: The MBP (68-82) fragment is also used to probe protein-peptide interactions relevant to myelin biology. Researchers employ the peptide in binding studies to characterize interactions with major histocompatibility complex molecules, co-stimulatory receptors, or antibody recognition sites. Such analyses contribute to a deeper understanding of the structural and functional determinants of immune recognition and the molecular underpinnings of neuroinflammatory processes.
2. High fat diet and GLP-1 drugs induce pancreatic injury in mice
4. The spatiotemporal control of signalling and trafficking of the GLP-1R
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More